“With the Board’s approval of the resolution of structured debt obligations, we will strengthen our balance sheet, increase financial flexibility and improve profitability,” said Kiran Mazumdar-Shaw, Chairman of Biocon Group.
“Our partnership with the State of California through Civica Inc under the CalRx initiative marks a milestone in expanding affordable access to insulin in the US, with potential to expand to other states,” she said. “With a resilient foundation, a differentiated portfolio and a clear strategy, we are well positioned to support growth and deliver long-term value to our stakeholders,” Shaw added.
The company’s generics business continued its steady performance in the second quarter with growth of 24%, primarily driven by an increase in the number of recently launched products in the US and EU, as well as growth in its core generic formulations business and API business.
“A key highlight of this quarter was the inauguration of Biocon’s first OSD manufacturing facility in the United States, an important step toward expanding access to our vertically integrated portfolio for patients in the region. We have begun filing applications for Semaglutide (gOzempic) in several markets including Canada and Brazil,” said Siddharth Mittal, CEO and Managing Director of Biocon Limited. Biocon Biologics posted 25% year-over-year revenue growth in the second quarter and an increase of more than 40% in the United States. EBITDA. Subsequently, revenues grew 11%, driven by market share expansion in key therapy areas and successful new product launches. “In the US, we continue to expand access to biosimilars by leveraging the strength of our commercial platform. In FY26, we launched four biosimilars in key global markets and remain on track to launch bDenosumab,” said Shreehas Tambe, CEO and Managing Director of Biocon Biologics.
#Biocon #results #Profit #rises #YoY #crore #strong #growth #biosimilars #generics